IP Verse

Glp-1 Compositions And Uses Thereof

Patent No. EP3474820 (titled "Glp-1 Compositions And Uses Thereof") was filed by Novo Nordisk on Aug 24, 2018. The application was issued on Feb 7, 2024.

Patent Summary

A pharmaceutical formulation for parenteral administration of semaglutide that combines semaglutide with no phenol. The formulation maintains semaglutide stability through the absence of phenol while achieving effective drug delivery through parenteral administration. The formulation provides a pH range of 6.0-10.0, which is suitable for semaglutide stability, and contains no preservatives. The formulation can be used for diabetes management and obesity treatment.

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADALVONov 7, 2024CASALPRIM CASTELLA
ELKINGTON AND FIFENov 7, 2024ELKINGTON AND FIFE
GENERICS UKNov 7, 2024TER MEER STEINMEISTER & PARTNER
POLPHARMANov 7, 2024ELKINGTON AND FIFE
SANDOZNov 7, 2024ELKINGTON AND FIFE
STRAWMANNov 7, 2024HOFFMANN EITLE
KRAUS & LEDERER PARTGMBBNov 6, 2024KRAUS & LEDERER PARTGMBB
MAIWALDNov 6, 2024MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3474820

NOVO NORDISK
Application Number
EP18756449A
Filing Date
Aug 24, 2018
Status
Granted And Under Opposition
Jan 5, 2024
Publication Date
Feb 7, 2024
External Links
Slate, Register , Google Patents